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Letters to the EditorPro-coagulant imbalance in patients with chronic liver diseaseTo the Editor:
We saw with interest the paper by Lisman et al. [1], published in
a recent issue of the Journal of Hepatology reporting normal or
even increased thrombin generation in patients undergoing liver
transplantation (LT) as compared to healthy subjects. This has
been interpreted as an in vitro ‘‘resistance” to the anti-coagulant
action of thrombomodulin [the physiological activator of protein
C (PC)]. This resistance is apparently due to the pro-coagulant
imbalance consequent to decreased levels of the anti-coagulant
drivers PC and antithrombin combined with increased levels of
the pro-coagulant driver factor (F)VIII. This is an interesting issue
and deserves comments.
We have already shown that patients with stable cirrhosis
possess a pro-coagulant imbalance detectable by thrombin gen-
eration assays performed with/without thrombomodulin [2].
The pro-coagulant imbalance observed in our cohort was mainly
due to decreased levels of PC and antithrombin combined with
increased levels of FVIII [2], which are typical features in cirrho-
sis. Furthermore, we also showed that the pro-coagulant imbal-
ance increases with the severity of the disease, as patients
classiﬁed as Child C had a more pronounced pro-coagulant imbal-
ance than patients classiﬁed as Child A–B [2]. Finally, we showed
that the extent of the imbalance observed in the Child C class was
slightly greater than that observed in plasma from patients who
were carriers of congenital-PC deﬁciency [2], a condition associ-
ated with an increased risk of venous thromboembolism. It can,
therefore, be concluded that the pro-coagulant imbalance is a
general and typical feature of patients with cirrhosis, and not
only of patients undergoing LT.
Concerning the cohort of patients investigated by Lisman et al.
[1], it is intriguing that they were still ‘‘pro-coagulant” even 5–
10 days after LT when PC was normalized. The authors surmise
that the pro-coagulant imbalance persists because of the persist-
ing increased levels of FVIII observed after LT. This requires fur-
ther comments. While PC levels are reduced pre-transplant
because of the impaired synthetic liver capacity, the increased
levels of FVIII are not explained by increased synthesis, but prob-
ably by decreased clearance from circulation (reviewed in Ref.
[3]). This is apparently mediated by two mechanisms involving
the von Willebrand factor (VWF) and the low density lipoprotein
receptor-related protein (LRP) [3]. VWF binds FVIII in vivo and
protects it from cleavage by plasma proteases and premature
clearance. Increased levels of VWF are typical features of patients
with cirrhosis and, therefore, they may be causally involved in
maintaining elevated circulating levels of FVIII in this condition
[3]. LRP, on the other hand, is a multi-functional ligand that medi-
ates the cellular up-take and degradation of plasma FVIII. LRP is
poorly expressed in cirrhosis and in conjunction with high VWF
might sustain the increased circulating levels of FVIII [3]. If the
above mechanisms hold true one would expect that, after trans-
plantation, patients have normal levels of PC as well as FVIII. The
reason why FVIII is persistently high after LT is of interest. One
reason could be that as FVIII is an acute phase reactant, it persists
to be high solely because of the pro-inﬂammatory effect medi-
ated by surgery [4,5].
We agree with Lisman et al. [1] that the pro-coagulant imbal-
ance observed in cirrhotics [2] supports the restrictive use of
plasma infusion in patients undergoing LT, but the restriction
should be extended also to stable patients when they undergo
invasive procedures, where plasma infusion is still common prac-
tice. We also agree that a more extensive use of anti-coagulant
drugs should be explored to reduce the incidence of post-trans-
plant thromboses, but again this should also be extended to
pre-transplant patients who develop portal- or peripheral-vein
thromboses. In this respect, we surmise that if the mechanism
of the pro-coagulant imbalance (i.e., decreased levels of PC com-
bined with increased levels of FVIII) holds true, thromboprophy-
laxis with vitamin-K antagonists (VKA), as it is currently done for
other categories of patients, could prove (at least in principle) less
suitable for patients with cirrhosis. VKA work, in fact, by decreas-
ing the activity of vitamin-K-dependent coagulation factors
including PC [6], which is already considerably reduced because
of impaired liver synthesis capacity. Therefore, one might specu-
late that VKA in cirrhosis might (paradoxically) exacerbate the
pro-coagulant imbalance leading to a much higher, increased
FVIII-to-PC ratio than that observed in patients with cirrhosis
not on VKA [2], especially if high initial doses of VKA are used.
Perhaps, the new oral antithrombotic drugs, which act directly
by inhibiting FXa or thrombin [7] might be more effective than
VKA in preventing recurrences in patients with cirrhosis after a
ﬁrst episode of venous thromboembolism. Furthermore, at vari-
ance with VKA, the new drugs do not require laboratory monitor-
ing to adjust their dosage [8], thus also circumventing the
problem of standardization of the INR, whose validity, as a labo-
ratory tool to monitor anticoagulation in patients with cirrhosis,
has been questioned and not yet resolved [9]. However, the efﬁ-
cacy and safety of the new antithrombotic drugs in the setting of
cirrhosis require investigation by appropriate clinical trials.
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Non-alcoholic fatty liver disease, alcohol intake and psoriasis
To the Editor:
We read the interesting report by Gisondi et al. published in a
recent issue of the Journal of Hepatology [1]. In this study, the
authors found that patients affected by severe psoriasis exhibited
an undiagnosed non-alcoholic fatty liver disease (NALFD) in
almost 50% of cases and suggested that psoriasis might be a
major risk factor for NALFD development.
The study shed light on this important issue, but there are
some concerns regarding selection of patients and the method
used to measure alcohol consumption.
Gisondi et al. state that the following amounts of alcoholic
beverages were considered one drink: ‘‘330 ml beer (containing
5% of alcohol), 150 ml wine (containing 12% of alcohol), and
40 ml strong alcohol (containing 50% of alcohol)”. Calculating
the amount of ethanol (EtOH) of each drink, it appears that the
beer contains about 13.2 g of EtOH, the wine 14.4 g and the
strong alcohol about 16 g. These data indicate that the group of
33 patients consuming 62 drinks had an alcohol intake of
26.4–32.0 g, depending on the type of beverages, whereas the
group of 20 patients consuming 3–4 drinks had an alcohol intake
of 39.6–64.0 g. Literature data have demonstrated that male
patients consuming more than 30 g and female patients consum-
ing more than 20 g of EtOH daily should be excluded from the
cohort when dealing with NAFLD because it is plausible that they
may already have an alcohol-related liver disease [2]. Conse-
quently, the authors should have excluded from their study the
group of patients consuming 3–4 beverages/day and apply differ-
ent cut-offs for males and females to include only patients ﬁtting
the above-mentioned criteria for NAFLD.
Moreover, Gisondi et al. have calculated the prevalence of
NAFLD in non-drinking patients (37%), which is lower compared
to the psoriasis-affected population considered in their study,
which include drinker and non-drinker patients. However, the
prevalence of liver disease should also be calculated in light ofmod-
erate drinkerswith psoriasis (consuming62 drinks and 3–4 drinks,
respectively) in order to analyze the contribution of these groups in
achieving a total NAFLD prevalence of 47% in psoriatic patients.
Co-morbidities in psoriasis have been deeply investigated in
the last years. The relationship between psoriasis and comorbi-
dities is probably related to the underlying chronic inﬂammatory
process. In this regard, emerging co-morbidities of psoriasis
include cardiovascular disease and metabolic syndrome, notably
obesity, dyslipidemia, and insulin resistance. Therefore, it is plau-
sible that chronic systemic inﬂammation, as observed in psoria-
sis, may also be responsible for NAFLD [3] and this association
should be considered when dealing with patients affected by pso-
riasis, as reported by Gisondi et al. However, the prevalence of
this association is probably overestimated and we believe that
an accurate evaluation of the daily alcohol intake using the
world-wide established alcoholic unit (corresponding to 8 g of
EtOH) may improve the selection of patients in which NAFLD
prevalence has to be calculated.
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